Drug Treatments

Summary:
10 therapeutic agents are in active clinical trials. Another 15 therapeutic agents are in planning stages. Currently the three (3) most likely drugs to be safe and effective are, for critically ill COVID-19 patients: (1) Remdesivir anti-viral drug by Gilead, and (2) Actemra/RoActemra (Tocilizumab) immunosuppressive drug by Roche, and for early stage SARS-CoV-2 infection: (3) Avigan (favipiravir) anti-viral drug by Fujifilm, Japan.
Published for educational purposes and social benefit, not for profit. Not a recommendation or endorsement. Always consult your doctor for medical advice.

July 2020

PRESS RELEASE | Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID) Anti-viral antibody cocktail REGN-COV2 is also in Phase 2/3 treatment trials following positive Phase 1 safety review

2020-07-12T08:38:11+00:00July 6th, 2020|

Reprinted for educational purposes and social benefit, not for profit.  NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc.  Jul 06, 2020, 07:00 ET ClinicalTrials.gov Identifier: NCT04452318 TARRYTOWN, N.Y., July 6, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, [...]

June 2020

JOHNS HOPKINS 2019 Novel Coronavirus Research Compendium (NCRC)

2020-06-28T03:54:06+00:00June 28th, 2020|

https://ncrc.jhsph.edu/ Our teams rapidly curate and assess emerging research on SARS-CoV-2 and COVID-19. We prioritize original, high-quality research for public health action and papers receiving significant attention, regardless of quality. [...]

CORONA (COvid19 Registry of Off-label & New Agents)

2020-06-27T14:10:25+00:00June 27th, 2020|

https://cdcn.org/corona/ CORONA (COvid19 Registry of Off-label & New Agents) Drug Repurposing for COVID-19 Our overarching vision:  A world where data on all treatments that have been used against COVID19 are maintained in a central repository [...]